CHI Insight Pharma Reports Research Reports

Title	Published	Price
Antibiotic R&D: Resolving the Paradox between Unmet Medical Need and Commercial Incentive By: CHI Insight Pharma Reports Antibiotic R&D: Resolving the Paradox between Unmet Medical Need and Commercial Incentive Author: Leslie A. Pray, PhD The current crisis in antibiotic R&D is attributed to an industry pipeline with few late-stage candidates capable \| more...	7/1/2008	$2,995.00
Blood-Brain Barrier: Bridging Options for Drug Discovery and Development By: CHI Insight Pharma Reports Strategies to develop small- and large-mol-ecule CNS drugs capable of crossing the blood-brain barrier (BBB) Interviews with leading researchers who are aggressively tackling the BBB challenge in CNS drug discovery and development Analysis \| more...	5/1/2008	$2,500.00
Systems Biology: A Disruptive Technology By: CHI Insight Pharma Reports This report focuses on the current and future applications of Systems Biology in drug discovery, specifically in pinpointing optimal individual targets, and combinations of targets, to overcome metabolic pathway redundancies, leading to efficacious and safe \| more...	5/1/2008	$2,995.00
Cardiotoxicity: Issues, Technologies, and Solutions for the Future By: CHI Insight Pharma Reports At least 50 companies have a claimed product or service relevant to cardiotoxicity screening, of which 29 have some clear focus on proarrhythmic cardiotoxicity or ion channel screening. This new report offers in-depth analysis of: \| more...	5/1/2008	$2,995.00
Inflammatory Directions: Strategies For Six Diseases With Unmet Needs By: CHI Insight Pharma Reports The pharmaceutical industry is exhaustively exploring novel targets in the search for new drugs to treat inflammatory diseases. Delving in-depth into these efforts, this report provides: An analysis of six diseases: rheumatoid arthritis, inflammatory \| more...	4/1/2008	$2,995.00
MicroRNAs: Commercial Products on the Horizon By: CHI Insight Pharma Reports With the first diagnostics set to debut within a year, the new research and development field of microRNAs is beginning to reveal its potential. This new report establishes a baseline for observing microRNAs’ maturation, including \| more...	3/1/2008	$2,995.00
Multiplex Assays in Translational Medicine: Technologies, Applications, and Future Directions By: CHI Insight Pharma Reports The development and growth of assay technologies has pushed translational medicine into a category unto itself. In a broad perspective on this field, this new report: Defines translational medicine by giving some historical background \| more...	2/1/2008	$2,995.00
Epigenetics: Technologies, Applications, and the Commercial Landscape By: CHI Insight Pharma Reports Epigenetics is one of the fastest-growing areas of the biological sciences. It’s also a budding industry. This new report offers in-depth analysis of: The definition, history, and current status of epigenetics Current and potential \| more...	2/1/2008	$2,995.00
Molecular Imaging in Drug R&D and Medical Practice: Technologies, Applications, Markets By: CHI Insight Pharma Reports The rapidly emerging field of molecular imaging is poised to open new vistas for basic researchers, scientists working in drug discovery and development, and physicians. This new report delves fully into: The history, evolution, and \| more...	1/1/2008	$2,995.00
Ophthalmological Therapeutics: A Promising and Profitable Market By: CHI Insight Pharma Reports The ophthalmology market, although a relatively small niche in the pharmaceutical industry, is more than worthwhile to track for multiple reasons: It is growing dynamically, and will likely continue this development unbroken for the \| more...	1/1/2008	$2,995.00
Kinase Therapeutic Pipelines: An Assessment of Targets and Agents in Development By: CHI Insight Pharma Reports Recent developments reflect the explosion in the number of kinase inhibitors that have entered clinical development in the past few years: By the end of 2006 seven kinase inhibitors had reached the market, three in \| more...	12/1/2007	$2,995.00
Molecular Diagnostics: A Rapidly Shifting Commercial and Technology Landscape By: CHI Insight Pharma Reports Molecular diagnostic tests are now used for a wide range of applications, including: Human clinical molecular diagnostic testing Identity testing Forensic testing Histocompatibility testing Within these \| more...	11/1/2007	$2,995.00
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment By: CHI Insight Pharma Reports In the more than 30 years since the first process for creating monoclonal antibodies, or mAbs, was introduced, they have remained a centerpiece of the growing biotechnology industry. Twenty-four therapeutic mAbs have been approved, several \| more...	10/1/2007	$2,995.00
Backup Compound Strategies: Best Practices for Reducing Phase II Risk By: CHI Insight Pharma Reports Backup compound planning has risen in importance as the percentage of R&D projects focused on unprecedented targets has skyrocketed. Heads of R&D and chemistry, therapeutic area heads, portfolio analysts, and project managers all recognize that \| more...	9/1/2007	$2,995.00
Adaptive Clinical Trials: Innovations in Trial Design, Management, and Analysis By: CHI Insight Pharma Reports The pharma industry is gradually coming to realize that the classically structured clinical trial does not offer enough flexibility to make use of continuously emerging knowledge that is generated as the trial progresses. This report \| more...	9/1/2007	$2,995.00
Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome By: CHI Insight Pharma Reports A growing number of companies and academic groups are reporting impressive progress in commercializing new sequencing platforms that offer orders of magnitude of improved throughput and cost. The prospect of routine, personalized genome sequencing is \| more...	8/1/2007	$2,500.00
Clinical Forecasting: A Novel Bayesian Tool for Predicting Phase III Outcomes By: CHI Insight Pharma Reports In recent years, there has been an explosion in predictive technologies to help researchers select only the most promising candidates for clinical development. The need for such tools is driven by the disastrous economic consequences \| more...	7/1/2007	$2,500.00
Disease-Related Biomarkers: Their Potential in Patient Screening, Prognosis, and Stratification By: CHI Insight Pharma Reports Expert guidance in managing discovery and development of disease-related biomarkers This report focuses on disease-related biomarkers, those related to disease screening, prognosis, and stratification—more specifically, disease-related molecular biomarkers. Aspects covered include: Historical and contextual \| more...	6/1/2007	$2,995.00
High Content Analysis: Technologies, Applications, Market Analysis By: CHI Insight Pharma Reports This new Insight Pharma report from Cambridge Healthtech Institute delivers the data and the analysis you need to stay on top of this fast-changing market: Quantitative survey (N=60) of the practices, plans, and \| more...	5/1/2007	$2,995.00
Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D By: CHI Insight Pharma Reports A worldwide epidemic of type 2 diabetes has been in progress since the mid-1980s, according to the World Health Organization. The worldwide number of diabetics was 30 million in 1985 and is projected to increase \| more...	5/1/2007	$2,995.00
Combination Drug/Diagnostic Products: Pathways to R&D and Commercial Success By: CHI Insight Pharma Reports This new report from CHI’s Insight Pharma Reports assesses the commercial opportunities and provides the information and guidance that companies need to steer clear of the pitfalls in combination drug/diagnostic R&D. Specifically, it provides: \| more...	5/1/2007	$2,995.00
Metabolic and Inflammatory Disease R&D: An Assessment of 5 Highly Promising Therapeutic Classes By: CHI Insight Pharma Reports At any given time, a number of drug targets are attracting considerable interest from different pharmaceutical companies. The emergence of such targets as hot topics of research usually becomes apparent before the introduction of clinical \| more...	4/1/2007	$2,995.00
Delivery Technologies for Protein Therapeutics: Assessment and Outlook By: CHI Insight Pharma Reports Some of biotech’s most celebrated successes include: clotting factors anticoagulants modern insulins growth hormone follicle-stimulating hormone hematopoietic growth factors interferons \| more...	3/1/2007	$2,995.00
Cytokine Therapies and Inhibitors: A Vibrant Pipeline and Active Approved Market By: CHI Insight Pharma Reports Cytokines have drawn immense interest from the pharmaceutical industry over the last two decades. Great effort has been devoted to finding ways to reproduce their effects—or to block their activity—in the quest to create novel \| more...	2/1/2007	$2,750.00
Biomarker SOPs: Getting Optimum Value from Your Biomarker Programs By: CHI Insight Pharma Reports As biomarkers have grown in importance throughout the pharma R&D cycle, managers have moved from informal, intuitive ways of dealing with biomarker discovery and implementation to more formal procedures. In all pharmaceutical companies, standard operating \| more...	1/1/2007	$3,000.00
Title	Published	Price

< prev 1 2 3 4 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2008, All Rights Reserved, MarketResearch.com
7/24/2008 - 4